2,644 results match your criteria Cutaneous B-Cell Lymphoma


Alopecic patches of the scalp: a variant of primary cutaneous follicle center B-cell lymphoma reported in a series of 14 cases.

J Eur Acad Dermatol Venereol 2019 Feb 4. Epub 2019 Feb 4.

INSERM, UMR976, Centre de Recherche sur la Peau.

Primary cutaneous follicle center lymphoma (PCFCL) is the most frequent primary cutaneous B-cell lymphoma. It presents usually with erythematous papules, plaques and tumors that predominate on the head, neck and upper trunk. The evolution is indolent but relapses are frequent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15477DOI Listing
February 2019
1 Read

Primary Cutaneous Large B-Cell Lymphomas: relevance of the 2017 WHO Classification.

Histopathology 2019 Feb 4. Epub 2019 Feb 4.

Pathology Department, University Hospital of Bordeaux, Hôpital Haut-Lévêque, 33604, Bordeaux Cedex, France.

Aims: We applied the 2017 WHO classification criteria to categorize a series of 64 primary cutaneous large B-cell lymphomas (PCLBCLs), containing a majority (⩾80%) of large-cells and a proliferative rate ⩾40%, raising the problem of the differential diagnosis between PCLBCLs, leg type (PCLBCLs-LT) or primary cutaneous follicle center lymphomas with large cell morphology (PCFCLs-LC). The aims were to determine reproducibility and prognostic relevance of the 2017 WHO criteria.

Methods And Results: Morphology and phenotype identified 32 PCLBCLs-LT and 25 PCFCLs-LC; 7 cases (11%) remained unclassified. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/his.13832
Publisher Site
http://dx.doi.org/10.1111/his.13832DOI Listing
February 2019
3 Reads

[Primary skin lymphomas: Current therapy].

Authors:
O Dereure

Ann Dermatol Venereol 2019 Jan 29. Epub 2019 Jan 29.

Unité Inserm U1058, département de dermatologie, université Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address:

Therapeutic progress in primary cutaneous lymphomas continues to be largely dominated by the T-cell lymphomas, towards which the great majority of recent therapeutic innovations have been directed. The latter include local treatments consisting either of relatively classical but "revamped" approaches involving different pharmaceutical forms (example: chlormethine gel) or else lower but seemingly equally effective dosages (electron therapy), or of more innovative approaches (example: UVA-1, dynamic phototherapy, imiquimod, resimiquimod). However, significant progress has been made chiefly in terms of systemic treatments with the emergence of "targeted" drugs that directly and specifically target tumour cells (monoclonal antibodies directed against CD30, CCR4 or CD158k) and the further development of "small" molecules such as histone deacetylase inhibitors and new cytostatics. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01519638183135
Publisher Site
http://dx.doi.org/10.1016/j.annder.2018.11.012DOI Listing
January 2019
4 Reads

Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.

J Am Acad Dermatol 2019 Jan 28. Epub 2019 Jan 28.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Whole body imaging is current standard of care for staging all patients presenting with skin lesion(s) of B-cell lymphomas (BCL), regardless of skin disease extent, however supporting data are lacking.

Objective: To determine the clinical utility of imaging in detection of systemic involvement in low grade cutaneous B-cell lymphoma presenting in the skin.

Methods: Retrospective cohort analysis of patients presenting with cutaneous lesions of BCLs at Memorial Sloan Kettering Cancer Center (MSKCC) and Stanford University (SU) from 1997-2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.037DOI Listing
January 2019
2 Reads

Response to «Cutaneous eruptions associated with hematologic malignancies : the need for a unifying nomenclature».

J Eur Acad Dermatol Venereol 2019 Jan 31. Epub 2019 Jan 31.

Service d'Oncodermatologie, Hôpital Robert Debré, Reims, France.

We read with interest Maglie et al's comments to "T-cell papulosis associated with B-cell malignancy (TCP-BCM): a distinctive clinicopathologic entity"(1,2). These authors conducted a study focusing on "eosinophilic dermatosis of hematologic malignancies" (EDHM) and TCP-BCM, and suggest that although this eruption is mostly associated with BCMs, it may also occur with other hematological malignancies (HM) such as acute myeloid leukemia or T-cell lymphoma, or even different inflammatory conditions. In our study, we excluded non B-cell malignancies because i) they are possibly associated with a wider spectrum of cutaneous manifestations (3,4) ii) in our clinical experience, TCP-BCM was always associated with chronic lymphocytic leukemia (CLL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15451DOI Listing
January 2019
6 Reads

Primary cutaneous marginal zone B-cell lymphoma of vulva in a pregnant woman.

Indian J Dermatol Venereol Leprol 2019 Mar-Apr;85(2):211-214

Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_295_18DOI Listing
January 2019
3 Reads

Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma: a rare and aggressive cutaneous lymphoma.

Cutis 2018 Dec;102(6):421-424

Department of Dermatology, St. Joseph Mercy Hospital, Ann Arbor, Michigan, USA.

Cutaneous B-cell lymphomas represent a group of lymphomas derived from B lymphocytes in various stages of differentiation. The skin can be the site of primary or secondary involvement of any of the B-cell lymphomas. The classification of primary cutaneous B-cell lymphomas has evolved as the use of immunohistochemical and molecular genetic techniques have become more widespread. Read More

View Article

Download full-text PDF

Source
December 2018
12 Reads

Dermoscopy in lymphoproliferative disorders - experience from a cutaneous lymphoma clinic in a tertiary cancer center.

J Am Acad Dermatol 2019 Jan 14. Epub 2019 Jan 14.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.12.064DOI Listing
January 2019
1 Read

Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.

J Cell Biochem 2019 Jan 16. Epub 2019 Jan 16.

The Second Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, P. R. China.

Osteosarcoma (OS) is a malignant neoplasia in bone, characterized with main occurrence in teenagers. Calycosin (CC), a bioactive compound, is found to play potent pharmacological effects against cancer. Our previous study indicates CC-exerted benefits for anti-OS effect. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.28360
Publisher Site
http://dx.doi.org/10.1002/jcb.28360DOI Listing
January 2019
4 Reads

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.

Drug Saf 2019 Jan 16. Epub 2019 Jan 16.

Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, SL9 7JA, UK.

Activation of phosphatidylinositol-3-kinase (PI3K) and downstream signalling by AKT/mammalian target of rapamycin (mTOR) modulates cellular processes such as increased cell growth, cell proliferation and increased cell migration as well as deregulated apoptosis and oncogenesis. The PI3K/AKT/mTOR pathway (particularly Class I PI3K isoforms) is frequently activated in a variety of solid tumours and haematological malignancies, making PI3K an attractive therapeutic target in oncology. Inhibitors of PI3K also have the potential to restore sensitivity to other modalities of treatments when administered as part of combination regimens. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40264-018-0778-4
Publisher Site
http://dx.doi.org/10.1007/s40264-018-0778-4DOI Listing
January 2019
10 Reads

CD5-Positive Intravascular Large B-Cell Lymphoma in a Patient with Wilson's Disease: Case Report and Review of the Literature.

Case Rep Pathol 2018 16;2018:5140586. Epub 2018 Dec 16.

Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 6 Ohio Drive, Suite 202, Lake Success, New York, 11042, USA.

Intravascular large B-cell lymphoma (IVLBCL) is a rare extra-nodal B-cell lymphoma that proliferates within small/intermediate blood vessels and capillaries while sparing large blood vessels and organ parenchyma. Clinical presentation is highly variable and may include B symptoms, neurological deficits, and/or cutaneous findings. The diagnosis of IVLBCL is difficult due to multiorgan involvement and nonspecific symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5140586DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311313PMC
December 2018
6 Reads

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Blood 2019 Jan 11. Epub 2019 Jan 11.

Hematopathology section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States.

Primary cutaneous lymphomas are a heterogeneous group of T-cell lymphomas and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-EORTC consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018 an updated version of the WHO-EORTC was published in the 4th edition of the WHO classification for Skin Tumours Blue Book. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-881268DOI Listing
January 2019
23 Reads

Primary Cutaneous Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma.

Am J Dermatopathol 2019 Jan 3. Epub 2019 Jan 3.

Oncologia Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland.

Large B-cell lymphomas include several subtypes. Recently, anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma has been delineated as a distinct entity involving mostly lymph nodes and rarely affecting extranodal sites. We describe the first case of a primary cutaneous ALK-positive large B-cell lymphoma in a 48-year-old man with a solitary nodule on the back, and describe the histologic and phenotypic features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001348DOI Listing
January 2019
8 Reads

SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

Clin Immunol 2018 Oct 25. Epub 2018 Oct 25.

Department of Molecular and Cellular Pathobiology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.

SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216616183043
Publisher Site
http://dx.doi.org/10.1016/j.clim.2018.10.015DOI Listing
October 2018
6 Reads

The clinical value of imaging in primary cutaneous lymphomas: Role of high resolution ultrasound and PET-CT.

Br J Radiol 2019 Jan 4:20180904. Epub 2019 Jan 4.

4 Dermatology Service, Hospital Universitario, Puerta de Hierro, Majadahonda , Madrid , Spain.

Background:: Primary cutaneous lymphoma is a rare extranodal non-Hodgkin's lymphoma confined to the skin. The data on the imaging findings of primary cutaneous lymphomas are largely lacking and the current diagnosis is based on clinical and histopathological examination. With the advances in dermatological ultrasound and molecular imaging, newer perspectives in the evaluation of cutaneous lymphomas are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20180904DOI Listing
January 2019
10 Reads

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Curr Oncol 2018 Dec 1;25(6):e592-e596. Epub 2018 Dec 1.

Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC.

Primary effusion lymphoma (pel) is a rare human herpesvirus 8 (hhv8)-related large B cell lymphoma with plasmablastic, immunoblastic, or anaplastic features that often carries a poor prognosis. This lymphoma occurs mainly in patients with hiv infection, most often with Epstein-Barr virus (ebv) co-infection, and usually presents as body cavity effusions or, less commonly, as extracavitary lesions without effusion (ec-pel). Chemotherapeutic treatment options are limited and require concurrent antiretroviral therapy (art). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291272PMC
December 2018
3 Reads

Primary cutaneous B-cell lymphoma: A single-center 5-year experience.

Indian J Cancer 2018 Apr-Jun;55(2):134-137

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.

Background: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_418_17DOI Listing
January 2019
3 Reads

Cutaneous B-Cell Lymphoblastic Lymphoma.

Am J Dermatopathol 2018 Dec 20. Epub 2018 Dec 20.

Departments of Dermatology and Cutaneous Biology.

B-cell lymphoblastic lymphoma (B-LBL) is a malignant neoplasm of immature B cells that accounts for only 10% of all cases of lymphoblastic lymphoma. Most commonly, B-LBL presents as bony lesions, but in rare cases, the disease manifests cutaneously. We present a case of simultaneous cutaneous and systemic presentation of B-LBL in an otherwise healthy 28-year-old man in which the lymphoblastic infiltrate stained positive for CD79a, Tdt, CD10, and CD20. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001347DOI Listing
December 2018
2 Reads

Low-Grade Cutaneous B-cell Lymphoma in African American Patients

J Drugs Dermatol 2018 Dec;17(12):1334 - 1337

Introduction: Cutaneous marginal zone lymphoma (CMZL) and cutaneous follicle center lymphoma (CFCL) are rare indolent cutaneous B-cell lymphomas (CBCL). Their incidence in African American (AA) patients is extremely low. While cutaneous T-cell lymphomas appear to be more aggressive in AA individuals, there is no data on the presentation and course of disease of CBCL in this group. Read More

View Article

Download full-text PDF

Source
December 2018
4 Reads

EBV mucocutaneous ulcers in the setting of pre-existing cutaneous T-cell lymphoproliferative disorders: A report of 2 cases.

JAAD Case Rep 2019 Jan 11;5(1):78-81. Epub 2018 Dec 11.

Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.10.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293026PMC
January 2019
2 Reads

Diffuse large B cell lymphoma: cutaneous presentation.

BMJ Case Rep 2018 Dec 17;11(1). Epub 2018 Dec 17.

Medical Oncology, Hospital de Santo Antonio dos Capuchos, Lisboa, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301616PMC
December 2018
1 Read

Merkel cell carcinoma arising in association with cutaneous T-cell lymphoma: A potential diagnostic pitfall.

J Cutan Pathol 2019 Mar 4;46(3):199-203. Epub 2019 Jan 4.

Department of Pathology, Michigan Medicine, Ann Arbor, Michigan.

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma with increased prevalence in patients with immunosuppression or B-cell neoplasms. To the best of our knowledge, an association with cutaneous T-cell lymphoma (CTCL) has not been previously described. In this report, we present two cases of MCC arising in the setting of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13404DOI Listing
March 2019
3 Reads

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.

Medicine (Baltimore) 2018 Dec;97(49):e13093

Department of Hematology.

Rationale: Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B lymphoid cells that exhibits diffuse growth patterns. Patients may present with nodal and/or extranodal disease. The most common extranodal site is the gastrointestinal tract, while skin is less common. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310597PMC
December 2018
2 Reads

[Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].

Magy Onkol 2018 Dec 15;62(4):204-213. Epub 2018 Oct 15.

Gyermekgyógyászati Intézet, Gyermekhematológiai-onkológiai nem önálló Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Hungary.

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. Read More

View Article

Download full-text PDF

Source
December 2018
6 Reads

Leishmania infection: Misdiagnosis as cancer and tumor-promoting potential.

Acta Trop 2018 Dec 7. Epub 2018 Dec 7.

Université Côte d'Azur, Inserm, C3M, Nice Cedex 3, France. Electronic address:

Given the prevalence of cancer and leishmaniasis worldwide, the presence of these two pathologies in the same tissue sample may be merely fortuitous. The clinical outcome of both diseases is under the control of innate and adaptive immunity, and in both cases these progressive diseases are characterized by an impaired host Th1 response. As a consequence, the Th2 cytokine microenvironment occurring in progressive leishmaniasis may potentially promote tumor cell proliferation and vice versa. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0001706X183132
Publisher Site
http://dx.doi.org/10.1016/j.actatropica.2018.12.010DOI Listing
December 2018
22 Reads

Primary cutaneous vs secondary cutaneous follicular lymphomas: A comparative study focused on BCL2, CD10, and t(14;18) expression.

J Cutan Pathol 2019 Mar 26;46(3):182-189. Epub 2018 Dec 26.

Department of Dermatology, Hospital del Mar. Parc de Salut Mar. IMIM, Barcelona, Spain.

Background: Primary cutaneous follicular center-cell lymphoma (PCFCL) is one of the most common types of cutaneous B-cell lymphoma. Differences in immunohistochemical expression of BCL2 and CD10 antigens along with the presence of t(14:18) translocation in neoplastic cells have been postulated as relevant clues in differentiating PCFCL from cutaneous lesions secondary to a systemic follicular lymphoma (SCFL). The aim of this study is to evaluate the significance and usefulness of these parameters in a large series of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13399DOI Listing
March 2019
14 Reads

Cutaneous B-Cell Lymphoma.

Hematol Oncol Clin North Am 2019 Feb;33(1):149-161

Section of Dermatology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address:

Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.08.006DOI Listing
February 2019
2 Reads
2.295 Impact Factor

Prevalence of CD20 cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011-2018) in the USA.

Vet Dermatol 2019 Feb 25;30(1):51-e14. Epub 2018 Nov 25.

Department of Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University of Florida, PO Box 100123, Gainesville, FL, 32610, USA.

Background: Limited information is known about the baseline frequency of canine CD20 positive ( ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published.

Objectives: To characterize the baseline frequency of CD20 staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vde.12703DOI Listing
February 2019
1 Read

Indicaxanthin from Opuntia Ficus Indica (L. Mill) impairs melanoma cell proliferation, invasiveness, and tumor progression.

Phytomedicine 2018 Nov 18;50:19-24. Epub 2018 Sep 18.

Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Università di Palermo, Via Archirafi 28, 90123 Palermo, Italy. Electronic address:

Background: A strong, reciprocal crosstalk between inflammation and melanoma has rigorously been demonstrated in recent years, showing how crucial is a pro-inflammatory microenvironment to drive therapy resistance and metastasis.

Purpose: We investigated on the effects of Indicaxanthin, a novel, anti-inflammatory and bioavailable phytochemical from Opuntia Ficus Indica fruits, against human melanoma both in vitro and in vivo.

Study Design And Methods: The effects of indicaxanthin were evaluated against the proliferation of A375 human melanoma cell line and in a mice model of cutaneous melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phymed.2018.09.171DOI Listing
November 2018
9 Reads

Papuloerythroderma-like cutaneous involvement of a CD62L subclone of T-cell prolymphocytic leukemia.

J Dermatol 2019 Jan 19;46(1):65-69. Epub 2018 Nov 19.

Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

We report the case of an 88-year-old Japanese man with erythrodermic involvement of T-cell prolymphocytic leukemia (T-PLL). He had a history of pharyngeal diffuse large B-cell lymphoma successfully treated with polychemotherapy including cyclophosphamide and epirubicin, 6 years before the current illness. He presented with numerous reddish, coalescing, flat-topped papules on the trunk and extremities, sparing the skin folds of the abdomen, the features of which mimicked those of papuloerythroderma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14702DOI Listing
January 2019
3 Reads

Morphological characterization of canine retrobulbar lymphoma.

Open Vet J 2018 14;8(4):367-373. Epub 2018 Oct 14.

Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand.

This report characterized seven cases of canine retrobulbar lymphoma that have been diagnosed during 2008 to 2014 by immunophenotyping of CD3 and Pax5. Classification of lymphoma were performed according to the revised WHO guidelines. Four retrobulbar lymphomas were of T-cell origin, while the others were of B-cell. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ovj.v8i4.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203897PMC
October 2018
2 Reads

Primary Cutaneous Composite Lymphomas.

Arch Pathol Lab Med 2018 Nov;142(11):1352-1357

From the Department of Pathology, University of Iowa Health Care, Iowa City (Dr Chen); and the Departments of Pathology (Drs Boyer and Hristov) and Dermatology (Dr Hristov), University of Michigan Medical Center, Ann Arbor.

Composite lymphomas have been defined as 2 distinct subtypes of lymphoma occurring at a single anatomic site. Composite lymphomas limited to the skin are a rare occurrence and pose a unique challenge. Many reported cases within the skin are combined B-cell and T-cell lymphomas, typically mycosis fungoides and a low-grade B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-028
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0283-RADOI Listing
November 2018
7 Reads

Primary Cutaneous Follicle Center Lymphoma.

Arch Pathol Lab Med 2018 Nov;142(11):1313-1321

From the Department of Pathology, University of Michigan Medical Center, Ann Arbor (Drs Skala and A. C. Hristov); the Department of Internal Medicine, Section of Radiation Oncology, Wright Patterson Air Force Base (Dr B. Hristov); and the Department of Dermatology, University of Michigan Medical Center (Dr A. C. Hristov).

Context.—: Primary cutaneous follicle center lymphoma is a low-grade B-cell lymphoma that is limited to the skin at diagnosis. It has a differential diagnosis that includes systemic/nodal follicular lymphoma secondarily involving the skin; primary cutaneous diffuse large B-cell lymphoma leg type; reactive lymphoid hyperplasia; and primary cutaneous marginal zone lymphoma. Read More

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2018-021
Publisher Site
http://dx.doi.org/10.5858/arpa.2018-0215-RADOI Listing
November 2018
11 Reads

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Histopathology 2018 Nov 4. Epub 2018 Nov 4.

Aix-Marseille University, Marseille, France.

Aims: This study sought to clarify the molecular pathways underlying the putative evolution from lymphomatoid papulosis (LyP) to cutaneous anaplastic large-cell lymphoma (c-ALCL) and lymph node invasion (LNI).

Methods And Results: We analysed nine sequential tumours from the same patient presenting with parallel evolution of LyP (n = 3) and c-ALCL (n = 1) with LNI (n = 1), combined with systemic diffuse large B-cell lymphoma (DLBCL) (n = 4). Clonality analysis showed a common clonal T-cell origin in the five CD30+ lesions, and a common clonal B-cell origin in the four DLBCL relapses. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/his.13783
Publisher Site
http://dx.doi.org/10.1111/his.13783DOI Listing
November 2018
15 Reads

Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.

Ann Diagn Pathol 2018 Oct 2;38:6-10. Epub 2018 Oct 2.

Neogenomics, Aliso Viejo, CA, United States of America; M.D. Anderson Cancer Center, University of Texas, Department of Hematopathology, Houston, TX, United States of America. Electronic address:

The recent 2017 update of the World Health Organization classification of lymphomas has significant changes from the previous edition. Subtypes of large B cell lymphoma and related aggressive B cell lymphomas are addressed. Clinicopathological features of entities as related to morphology, immunophenotype, cell of origin, and molecular/genetic findings are reviewed with emphasis on changes or updates in findings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10929134183028
Publisher Site
http://dx.doi.org/10.1016/j.anndiagpath.2018.09.014DOI Listing
October 2018
15 Reads

A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type.

Cutis 2018 Sep;102(3):E31-E34

Department of Dermatopathology, Western University of Health Sciences, Pomona, California, USA.

Primary cutaneous diffuse large B-cell lymphoma, leg type (DLBCLLT) is a rare, intermediately aggressive form of primary cutaneous B-cell lymphoma (CBCL) that is characterized by the presence of large round cells on histopathology. Clinically, patients present with red-brown nodules on the distal legs. The prognosis is less favorable than other types of CBCLs, with a 5-year survival rate of 50%. Read More

View Article

Download full-text PDF

Source
September 2018
21 Reads

Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma.

Cutis 2018 Sep;102(3):179-182

Department of Dermatology, Saint Joseph Mercy Hospital, Ann Arbor, Michigan, USA.

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma that is characterized by lymphadenopathy, night sweats, fever, weight loss, and autoimmune phenomena. Cutaneous manifestations are present in up to 50% of cases, but few cases are reported in the dermatologic literature. We present a case of AITL that manifested in the skin. Read More

View Article

Download full-text PDF

Source
September 2018
7 Reads

Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall.

J Cutan Pathol 2019 Feb 10;46(2):102-110. Epub 2018 Dec 10.

Département de Biopathologie, CHU Montpellier, Hôpital Gui De Chauliac, Montpellier, France.

Background: We report the cases of three patients presenting skin lesions whose biopsies showed nodular polymorphic infiltrates consisting of lymphocytes, plasma cells, histiocytes, eosinophils, B blasts, and Hodgkin Reed-Sternberg (HRS)-like cells. Two of them were initially diagnosed as classical Hodgkin lymphoma (cHL), on the other hand, the last one as a B-cell lymphoma. All patients have been treated for angioimmunoblastic T-cell lymphoma (AITL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13382DOI Listing
February 2019
6 Reads

PCR-based clonality analysis of antigen receptor gene rearrangements in canine cutaneous plasmacytoma.

Vet J 2018 Nov 20;241:31-37. Epub 2018 Sep 20.

North Lab, 2-8-35, Hondori, Shiroisi-ku, Sapporo, Hokkaido 003-0027, Japan.

Plasmacytomas are discrete, B cell-derived, round cell tumours that sometimes are difficult to distinguish from canine cutaneous histiocytomas or T cell lymphosarcomas (lymphomas). Diagnosis of plasmacytomas relies on morphological observations and immunohistochemistry for multiple myeloma oncogene-1 (MUM-1) and cluster of differentiation 3 (CD3). Clonality testing often is used as an adjunct diagnostic tool to examine lymphoproliferative diseases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10900233183058
Publisher Site
http://dx.doi.org/10.1016/j.tvjl.2018.09.010DOI Listing
November 2018
10 Reads

Effects of insulin-like growth factor binding protein 3 on apoptosis of cutaneous squamous cell carcinoma cells.

Onco Targets Ther 2018 5;11:6569-6577. Epub 2018 Oct 5.

Department of ICU, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266071, China,

Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common carcinoma worldwide. Clinical treatment for patients with CSCC remains non-ideal. Insulin-like growth factor binding protein 3 (IGFBP3), a member of the insulin-like growth (IGF) system, participates in several biological processes, including cellular proliferation and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S167187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178943PMC
October 2018
3 Reads

Image Gallery: 308-nm ultraviolet B excimer laser treatment for cutaneous B-cell lymphoma nodular lesions on the face.

Authors:
H Miura

Br J Dermatol 2018 Oct;179(4):e166

Department of Dermatology, Osaka Minato Central Hospital, 1-8-30 Chikko, Minato-ku, Osaka, 552-0021, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.16986DOI Listing
October 2018
1 Read

Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients.

Int J Dermatol 2018 Oct 7. Epub 2018 Oct 7.

Academia Nacional de Medicina, Ciudad de Buenos Aires, Argentina.

Background: The aim of this study was to determine the relative frequency of primary cutaneous lymphoma (PCL) in Argentina according to the new World Health Organization (WHO)-European Organization for the Research and Treatment of Cancer (EORTC) classification system.

Methods: A total of 416 patients from 21 dermatology services were included during a 5-year period (2010-2015); these patients were classified using WHO-EORTC criteria.

Results: There were 231 (55. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.14262
Publisher Site
http://dx.doi.org/10.1111/ijd.14262DOI Listing
October 2018
17 Reads

Canine and Feline Cutaneous Epitheliotropic Lymphoma and Cutaneous Lymphocytosis.

Authors:
Kathryn A Rook

Vet Clin North Am Small Anim Pract 2019 Jan 24;49(1):67-81. Epub 2018 Sep 24.

Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, 3900 Delancey Street, Philadelphia, PA 19104, USA. Electronic address:

Cutaneous lymphomas are divided into categories based on histologic evaluation of the skin and location of neoplastic lymphocytes. Epitheliotropic cutaneous lymphoma, also known as cutaneous T-cell lymphoma, is diagnosed when neoplastic lymphocytes show tropism for the epidermis and these cells infiltrate the epidermis and adnexae. In diagnosis of nonepitheliotropic cutaneous lymphoma, neoplastic lymphocytes are found mostly in the dermis and/or subcutis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cvsm.2018.08.007DOI Listing
January 2019
8 Reads

Primary cutaneous diffuse large B-cell lymphoma, leg type, localized in the right periorbital region.

J Dermatol 2018 Sep 19. Epub 2018 Sep 19.

Department of Dermatology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14657DOI Listing
September 2018
10 Reads

Dermoscopy of Lymphomas and Pseudolymphomas.

Dermatol Clin 2018 Oct 14;36(4):377-388. Epub 2018 Aug 14.

Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Viale Risorgimento 80, Reggio Emilia 42123, Italy; Dermatology Department, University of Modena and Reggio Emilia, via del Pozzo 71, Modena 41124, Italy.

Primary cutaneous lymphomas are a heterogeneous group that includes 2 main groups of primary T- and B-cell lymphomas, which can involve the skin with distinct variability in clinical presentation, histopathology, immunophenotypes, molecular signature, and prognosis. The authors describe the most frequent clinical forms of cutaneous lymphomas and their dermoscopic features. Even if the diagnosis of these entities is still based on a cellular level and the literature on dermoscopy in cutaneous lymphomas is limited and, for several entities it is based only on single case reports/case series, we think that know how they appear also in dermoscopy can be useful for helping in the clinical diagnosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07338635183107
Publisher Site
http://dx.doi.org/10.1016/j.det.2018.05.005DOI Listing
October 2018
16 Reads